China’s Brain-Computer Interface Start-up Scene Is Moving From Labs to Commercialization

Brain-computer interfaces (BCIs) are no longer just a moonshot story centered on Neuralink.

In a recent TechCrunch report, China’s BCI industry is described as moving from research into commercial scale, with momentum coming from policy support, clinical trials, and investor interest. The article highlights startups working on both implantable and non-invasive approaches, including NeuroXess and Gestala.

One key driver is policy. TechCrunch notes that in August 2025, China’s industry ministry and six other agencies issued a roadmap targeting BCI technical milestones by 2027, industry standards, and a fuller supply chain by 2030. The story also notes provincial efforts to set medical service pricing for BCI, which could help move the technology toward reimbursement and broader adoption.

The report also points to a mix of practical advantages: large clinical populations, lower research costs, strong manufacturing capacity, and growing state/private investment. It cites examples such as an 11.6 billion yuan brain science fund announced in Shenzhen and recent start-up fundraising/IPO activity in the sector.

What makes this especially interesting is the split in strategy. Some companies are pursuing invasive implants (higher precision, higher risk), while others are focusing on noninvasive systems such as EEG headsets or ultrasound-based BCIs (lower precision, but easier adoption and potentially faster commercialization).

TechCrunch notes expectations that healthcare will remain the main use case in the next few years, even as founders talk about longer-term “human augmentation” possibilities.

This is a niche field, but it may become one of the most important battlegrounds in neurotech over the next decade.

author: Jamie Rina